Investing has been my hobby for many years. I am an engineer in Silicon Valley.
I am not an investment adviser. None of my writings should be interpreted as investment advice. Please get an investment adviser and do your own due diligence before investing.
Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
I am a Ph.D. level scientist at a major pharmaceutical company. Previously I was an NIH Cancer Postdoctoral fellow at UPENN. Through my extensive research background, I am able to quickly decipher clinical information and act on it. I specialize in analyzing and trading biotech/healthcare stocks both long and short. I maintain a few core positions and trade clinical events based on extensive research to realize large percentage profits. I am open to opportunities in consulting for financial firms or local advisors. Please contact me if you are interested.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Follow me on Twitter: @NewConstructs
David is CEO of New Constructs (www.newconstructs.com), an independent research firm that leverages proprietary technology to find key insights from the Financial Footnotes of 10Ks and 10Qs. Having analyzed over 70,000 annual reports and their Financial Footnotes, New Constructs helps protect clients from the red flags/unknowns in SEC filings.
David is a distinguished investment strategist and corporate finance expert. He is a member of FASB's Investors Advisory Committee, and he is author of the Chapter “Modern Tools for Valuation” in The Valuation Handbook (Wiley Finance 2010).
David's insights into the markets and his stock picks have been popular with a wide variety of media outlets.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Check out my record of Seeking Alpha recommendations here: https://www.tipranks.com/experts/ptsd-trader
I'm Steven Chase, battle-scarred trader and investor since my first (dreadful) investment in "Iomega" back in 1995. I am the Managing Partner of Rosemarkie Capital Partners LLC. In another life I wrote and managed a small cap newsletter which received praise from Barrons. Further, I am a Director of Software Development at a firm in Northern Virginia. I find story stocks, invest, ride the trend, and then get off. I've traded stocks, options, futures, commodities and written automated trading systems.
During the IPO season Francis Gaskins, editor of IPOdesktop.com & director of research for Equities.com, regularly appears on CNBC TV, Bloomberg, thestreet.com & other financial cable channels. On the day of the Visa IPO he appeared on four cable TV financial shows including Bloomberg & CNBC.
Over the past five years he has been quoted over 500 times by such financial media as the Wall Street Journal, Bloomberg, Reuters, Associated Press, USA Today among others. Those quotes are available at IPOdesktop.com.
His varied personal interests include violin playing. For example, he is concertmaster of the Palisades Symphony. He also holds an MBA from Harvard Business School (finance) and an AB from Princeton University (economics).
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek, email him directly: email@example.com (mailto:firstname.lastname@example.org)
Own over 50 dividend paying stocks. Our holdings by sector. Animal Health/Dental: PDCO. Chemical/Agriculture: DOW, DD, FMC and MON. Consumer Defensive: KO, PG, MO, KMB, GIS, MDLZ, CLX, CL, KHC, HSY and SJM. Consumer Cyclical: SBUX, NKE and COH. Healthcare: ABT, ABBV, BMY,BAX, DGX, JNJ, LLY, PFE, MRK and HYH. Tech: ADP, ORCL, IBM, INTC, GLW, HPQ, HPE, NATI and TXN. Industrial: EMR, ITW, MMM, HON and GE. Financial: FITB. Telecom: T and VZ. Utility: AEP Miscellaneous: AVY, CDK, FAST, FBHS and SPGI.
I began investing at the age of 14 and, at the age of 21, secured a job as a financial consultant at a top Wall Street firm. At 23, I was managing $65 million in client funds. Ultimately frustrated by Wall Street's prevalent practice of contradictory buy-side/sell-side analysis and behavior, I obtained my MBA from a top business school and became a proprietary trader contributing to a successful firm.
Having studied options trading, finance theories, efficient markets and economics, I learned that although not worthless, formal education was ultimately irrelevant to peak performance in real-world market application. Upon achieving consistent above-market returns, I started my own fund just 1 day before the market peak in October, 2007. Now I look to share ideas with the investing/trading community to help offset the toxic practices so prevalent on Wall Street.
Exec for nearly 20 yrs in Silicon Valley. Started in semis, then moved to software and mobile devices. Seek companies greatly undervalued and misunderstood by the market, but whose business I understand well. Usually long plus some options to pass the time.
I'm a radiologist by trade, but the goal is to leverage that medical knowledge as a competitive advantage in the markets. I aim to include all of the following in my analyses to ensure high quality: 1) quantitative estimates; 2) new information or inferences that are not already disseminated throughout the market; and 3) hypotheses that are testable, i.e. can be proved right or wrong. I have a serious allergy to question marks and will never, ever include one in an article title.
My dream is to co-found a biotech and bring a cure from the lab to the bedside. In the meantime, saving lives in clinical practice is a perfectly acceptable alternative.
Please note that all opinions I express on this website reflect my personal beliefs only and are completely independent of my current or past employers and/or affiliated institutions.
Lowenthal Capital Partners is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Law School.